We are live on ! Find out more
HM

HealthCor Management Portfolio holdings

AUM $109M
1-Year Est. Return 10.64%
This Fund
S&P 500
This Quarter Est. Return
-2.59%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
-$184M
Cap. Flow
-$103M
Cap. Flow %
-4.44%
Top 10 Hldgs %
48.71%
Holding
92
New
20
Increased
22
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$139M
2
COR icon
Cencora
COR
+$76M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$69.6M
4
CNC icon
Centene
CNC
+$65.7M
5
MCK icon
McKesson
MCK
+$56.3M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$106M
2
HUM icon
Humana
HUM
+$106M
3
DHR icon
Danaher
DHR
+$103M
4
TMO icon
Thermo Fisher Scientific
TMO
+$92.3M
5
CVS icon
CVS Health
CVS
+$91.6M

Sector Composition

Rank Sector Weight
1 Healthcare 88.69%
2 Consumer Discretionary 4.5%
3 Real Estate 3.92%
4 Financials 1.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMA
51
ImageneBio Inc
IMA
$64.6M
$4.29M 0.19%
28,329
-3,134
-10% -$455K
GHRS icon
52
GH Research
GHRS
$2.08B
$3.64M 0.16%
164,912
-85,088
-34% -$1.73M
ABGI
53
DELISTED
ABG Acquisition Corp. I
ABGI
$3.21M 0.14%
329,400
– –
OMEG
54
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$2.64M 0.11%
271,032
-6
-0% -$59
SRSAU
55
DELISTED
Sarissa Capital Acquisition Corp. Unit
SRSAU
$2.62M 0.11%
262,150
– –
RCUS icon
56
Arcus Biosciences
RCUS
$3.64B
$2.44M 0.11%
+70,050
New +$2.18M
EUCRU
57
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
$2.32M 0.1%
234,180
– –
VCYT icon
58
Veracyte
VCYT
$3.8B
$2.31M 0.1%
+49,640
New +$2.17M
RVNC
59
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.27M 0.1%
+81,500
New +$2.33M
MRTX
60
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.75M 0.08%
+9,890
New +$1.59M
MRUS
61
DELISTED
Merus
MRUS
$1.56M 0.07%
70,898
-25,540
-26% -$548K
PRCT icon
62
Procept Biorobotics
PRCT
$1.17B
$1.43M 0.06%
+37,400
New +$1.44M
ALNY icon
63
Alnylam Pharmaceuticals
ALNY
$29.3B
$1.42M 0.06%
+7,510
New +$1.41M
DICE
64
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$1.4M 0.06%
+42,800
New +$1.46M
JYAC
65
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.37M 0.06%
140,680
– –
AVIR icon
66
Atea Pharmaceuticals
AVIR
$420M
$1.28M 0.06%
+36,580
New +$1.01M
JNJ icon
67
Johnson & Johnson
JNJ
$625B
$1.18M 0.05%
+7,280
New +$1.24M
IMGN
68
DELISTED
Immunogen Inc
IMGN
$1.13M 0.05%
+200,000
New +$1.16M
ATAI icon
69
AtaiBeckley Inc
ATAI
$2.68B
$1.11M 0.05%
75,000
– –
LGV.WS
70
DELISTED
Longview Acquisition Corp. II Redeemable Warrants, each whole Warrant exercisable for one share of Class A Common Stock, each at an exercise price of $11.50 per share
LGV.WS
$551K 0.02%
427,178
– –
EQRXW
71
DELISTED
EQRx, Inc. Warrant
EQRXW
$214K 0.01%
99,998
– –
OHPAW
72
DELISTED
Orion Acquisition Corp. Warrant
OHPAW
$88K ﹤0.01%
137,305
– –
MSACW
73
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$59K ﹤0.01%
82,663
– –
AMGN icon
74
Amgen
AMGN
$222B
– –
-158,280
Closed -$38.6M
DAWN
75
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-103,717
Closed -$2.36M
1 2
3
4

Similar funds

IA
Integrity Advisory Overland Park, Kansas $109M AUM 15.71% 1-Year Est. Return
EPC
Emerson Point Capital Larchmont, New York $108M AUM 19.03% 1-Year Est. Return
TCMV
Technology Crossover Management VII Menlo Park, California $107M AUM 51.05% 1-Year Est. Return
SI
Salesforce Inc San Francisco, California $114M AUM 53.18% 1-Year Est. Return
HCWM
Harrison & Co Wealth Management Roanoke, Virginia $103M AUM 9.82% 1-Year Est. Return
PC
Phoenician Capital New York $117M AUM 9.46% 1-Year Est. Return
RF
Resolute Financial Newburyport, Massachusetts $118M AUM 11.75% 1-Year Est. Return
AWM
Align Wealth Management Oklahoma City, Oklahoma $118M AUM

HealthCor Management's Q3 2021 Portfolio in Review

As of Q3 2021, HealthCor Management held 92 positions worth $2.32B, down 7.4% from $2.5B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

HealthCor Management withdrew a net $103M in Q3 2021, closing 19 positions and reducing 16 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 88% a quarter earlier, followed by Consumer Discretionary and Real Estate.

Against the trend, HealthCor Management opened a new position in Jazz Pharmaceuticals worth $60M.

  • HealthCor Management's largest Q3 2021 buy was Jazz Pharmaceuticals: 460,790 shares worth $60M.
  • HealthCor Management added most to Bristol-Myers Squibb in Q3 2021, an estimated $139M increase.
  • HealthCor Management's biggest Q3 2021 reduction was CVS Health, cutting an estimated $91.6M.
  • HealthCor Management fully exited Regeneron Pharmaceuticals in Q3 2021, selling an estimated $106M.
  • HealthCor Management's ten largest holdings make up 49% of its $2.32B portfolio in Q3 2021.
  • HealthCor Management opened 20 new positions and closed 19 in Q3 2021.
  • HealthCor Management's portfolio value fell 7.4% quarter-over-quarter to $2.32B.

Based on HealthCor Management's 13F filing for Q3 2021, filed 15 Nov 2021.